REVIEW

Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates?

Afif El-Khuffash and Eleanor J Molloy

Department of Neonatology, National Maternity Hospital, Dublin, Ireland

Correspondence to:
Correspondence to:
Eleanor J Molloy
Department of Neonatology, National Maternity Hospital, Holles St, Dublin 2, Ireland; elesean{at}hotmail.com

B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NTpBNP) have a major role in screening and diagnosis of cardiac disease and monitoring of the treatment response in children and adults. This review discusses the evidence underpinning the potential benefits of these natriuretic peptides in neonatology. They may serve as a useful adjunct to echocardiography in the diagnosis of patent ductus arteriosus and its response to treatment and the diagnosis of persistent pulmonary hypertension of the newborn. However, more work is needed to explore the possible roles of BNP/NTpBNP in the management of sepsis and monitoring of cardiac performance in neonates.

Abbreviations: BNP, B-type natriuretic peptide; NTpBNP, N-terminal-pro-BNP; PPHN, persistent pulmonary hypertension of the newborn

Keywords: preterm infant; sepsis; ventricular function; patent ductus arteriosus; natriuretic peptides; BNP; NT pro-BNP

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• El-Khuffash, A, Barry, D, Walsh, K, Davis, P G, Molloy, E J (2008). Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. Arch. Dis. Child. Fetal Neonatal Ed. 93: F407-F412 [Abstract] [Full Text]